|
Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives